因子X联合活化因子VII在稀释性凝血病中的促凝血活性
该体外研究将活化因子VII与因子X按1:10组合(FVIIa/FX),在健康志愿者及心脏手术患者的稀释血浆中评估凝血酶生成。结果显示FVIIa/FX较单用rFVIIa或血浆更有效改善凝血酶生成,且所需FVIIa剂量显著更低。
要点
- FVIIa/FX在稀释血浆中缩短滞后时间并提高凝血酶生成峰值,效果优于单用rFVIIa。
- FVIIa/FX所需FVIIa剂量(0.35 μg/mL)显著低于rFVIIa(6.4 μg/mL)达到类似效果。
- 血浆联合FVIIa/FX比单用FVIIa/FX更有效缩短凝血时间。
核心结论
- FVIIa与FX组合在稀释性凝血病模型中改善凝血酶生成优于单用rFVIIa或血浆。
研究设计与样本
- 体外研究,血浆来自9名健康志愿者和12名心脏手术患者,评估体外50%稀释血浆和体外循环后体内稀释血浆。
主要发现
- 在稀释血浆中,FVIIa/FX或rFVIIa均缩短滞后时间并提高凝血酶生成峰值。
- FVIIa/FX在0.35 μg/mL时对滞后时间的改善程度大于rFVIIa在6.4 μg/mL时。
- 凝血酶原复合物通过提高凝血酶原水平增加峰值但未缩短滞后时间。
- 20%血浆置换未改善任何凝血酶生成变量。
- 在心脏手术患者体外循环后样本中观察到类似凝血酶生成模式。
关键数值与推荐
- FVIIa/FX浓度基于FVIIa水平为0.35、0.7和1.4 μg/mL,rFVIIa为1.4、2.8和6.4 μg/mL。
- 凝血酶原复合物剂量为0.3国际单位,血浆置换为20%。
- FVIIa/FX所需FVIIa剂量(1.4-2.8 μg/mL)低于血友病旁路治疗中报告的剂量。
临床怎么用
- FVIIa/FX可能作为心脏手术相关稀释性凝血病的促凝血选择,所需FVIIa剂量较低。
- 血浆联合FVIIa/FX可能比单用FVIIa/FX更有效恢复凝血。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recombinant activated factor VII (rFVIIa) concentrate reduces allogeneic blood transfusions, but it may increase thromboembolic complications in complex cardiac surgery. The mixture of activated factor VII (FVIIa) and factor X (FX) (FVIIa/FX) (FVIIa:FX = 1:10) is a novel bypassing agent for hemophilia patients. We hypothesized that the combination of FX and FVIIa could improve thrombin generation (TG) in acquired multifactorial coagulation defects such as seen in cardiac surgery and conducted in vitro evaluation of FVIIa/FX in parallel with other coagulation factor concentrates using in vitro and in vivo diluted plasma samples. METHODS: Plasma samples were collected from 9 healthy volunteers and 12 cardiac surgical patients. We measured TG (Thrombinoscope) using in vitro 50% dilution plasma and in vivo dilution plasma after cardiopulmonary bypass, in parallel with thromboelastometry (ROTEM) and standard coagulation assays. In vitro additions of FVIIa/FX (0.35, 0.7, and 1.4 μg/mL, based on the FVIIa level), rFVIIa (1.4, 2.8, and 6.4 μg/mL), prothrombin complex concentrate (0.3 international unit), and 20% plasma replacement were evaluated. RESULTS: In diluted plasma, the addition of either FVIIa/FX or rFVIIa shortened the lag time and increased the peak TG, but the effect in lag time of FVIIa/FX at 0.35 μg/mL was more extensive than rFVIIa at 6.4 μg/mL. Prothrombin complex concentrate increased peak TG by increasing the prothrombin level but failed to shorten the lag time. No improvement in any of the TG variables was observed after 20% volume replacement with plasma. The addition of factor concentrates normalized prothrombin time/international normalized ratio but not with plasma replacement. In cardiac patients, similar patterns were observed on TG in post-cardiopulmonary bypass samples. FVIIa/FX shortened clotting time (CT) in a concentration-dependent manner on CT on thromboelastometry. Plasma replacement did not improve CT, but a combination of plasma and FVIIa/FX (0.35 μg/mL) more effectively shortened CT than FVIIa/FX alone. CONCLUSIONS: The combination of FVIIa and FX improved TG more efficiently than rFVIIa alone or plasma in dilutional coagulopathy models. The required FVIIa dose in FVIIa/FX was considerably lower than those reported during bypassing therapy in hemophilia patients (1.4-2.8 μg/mL). The combination of plasma could restore coagulation more efficiently compared to FVIIa/FX alone. Lesser FVIIa requirement to exert procoagulant activity may be favorable in terms of reducing systemic thromboembolic complications.
引用
- Takeshita S, Ogawa S, Nakayama Y, et al. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy. Anesth Analg. 2019. PMID: 30320649. doi:10.1213/ANE.0000000000003858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。